Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Caroxime sodium sulfonate

Phase 3Small molecule

CChengdu University of Traditional Chinese Medicine

Caroxime sodium sulfonate is one of 2 small molecule programs targeting Perioperative Bleeding. It is currently in Phase 3.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Perioperative BleedingNot yet recruiting

Perioperative BleedingPhase 3

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Perioperative Bleeding

#DrugCompanyPhaseTrials

Cyklokapron

Caroxime sodium sulfonate

CChengdu University of Traditional Chinese Medicine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Perioperative Bleeding1 trial

Analysis of the Clinical Efficacy of Intravenous Application of Hemostatic Drugs in Improving the Clarity of Vision Under Endoscope, Perioperative Bleeding Volume and Anti-inflammatory Effect of Spinal Endoscopic Lumbar Fusion

Not yet recruiting·—·Phase 4·NCT06255366·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Caroxime sodium sulfonate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Caroxime sodium sulfonate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Caroxime sodium sulfonate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chengdu University of Traditional Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CChengdu University of Traditional Chinese Medicine

Related News